FMA
TRIL

FNY Managed Accounts’s Trillium Therapeutics Inc. TRIL Stock Holding History

FNY Managed Accounts’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,500
Closed -$13.5K – 456
2014
Q4 		$13.5K Buy
+1,500
New +$11.7K 0.02% 169

Other funds holding TRIL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $1.14B AUM 48.66% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

FNY Managed Accounts's TRIL Position: Q1 2015 in Review

FNY Managed Accounts sold out of Trillium Therapeutics Inc. (TRIL) in Q1 2015, closing a stake of 1,500 shares — an estimated $13.5K sold.

FNY Managed Accounts first reported a position in TRIL in Q4 2014 and held it in 1 quarter. The position peaked at $13.5K in Q4 2014. 14 funds tracked by Wall St. Rank hold TRIL as of Q1 2015.

  • FNY Managed Accounts reported no remaining Trillium Therapeutics Inc. position as of Q1 2015 after selling out during the quarter.
  • FNY Managed Accounts sold 1,500 Trillium Therapeutics Inc. shares in Q1 2015, an estimated $13.5K.
  • FNY Managed Accounts first reported a position in Trillium Therapeutics Inc. in Q4 2014 and held it in 1 quarter.
  • FNY Managed Accounts's Trillium Therapeutics Inc. position peaked at $13.5K in Q4 2014.
  • 14 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q1 2015.

Based on FNY Managed Accounts's 13F filing for Q1 2015, filed 6 May 2015.